Journal of Cell Science & Therapy
Open Access

Transcription Factors as Therapeutic Targets: Their Role in Tumorigenesis

Renan Kashem^{* *}Correspondence: Renan Kashem, Department of Anatomy, University of California San Francisco, San Francisco, California, USA, Email:

Author info »

Description

Transcription Factors (TFs) are critical regulators of gene expression that control various cellular processes, including differentiation, proliferation, and apoptosis. In the context of cancer, these molecules often become aberrantly activated or mutated, driving the uncontrolled growth and spread of tumor cells. As key players in tumorigenesis, transcription factors not only influence cancer initiation and progression but also contribute to metastasis, drug resistance, and immune evasion [1].

Role of transcription factors

Cancer is a complex disease characterized by the accumulation of genetic mutations and dysregulation of cellular processes. Transcription factors are pivotal in regulating these processes, and their misregulation often plays a key role in the initiation and progression of cancer. Transcription factors control the expression of genes involved in the cell cycle, and their dysregulation can result in uncontrolled cell division. For instance, the E2F family of transcription factors, which regulate the transition from the G1 to the S phase of the cell cycle, is often upregulated in cancer cells [2].

Similarly, the MYC family of transcription factors promotes the expression of genes that drive cell division. MYC is frequently overexpressed or amplified in a variety of cancers, contributing to tumorigenesis by accelerating cell cycle progression and inhibiting cell differentiation [3]. Transcription factors also regulate the expression of genes involved in tumor suppression and programmed cell death (apoptosis). Mutations in tumor suppressor genes, such as p53, often lead to the loss of normal apoptotic signaling, allowing cancer cells to evade death and accumulate further mutations [4].

Cancer metastasis, the spread of tumor cells to distant organs, is a key factor in cancer progression and patient prognosis. Transcription factors regulate the expression of genes that control cell migration, invasion, and Epithelial-Mesenchymal Transition (EMT) [5]. Transcription factors also influence the tumor microenvironment by regulating angiogenesis the formation of new blood vessels that supply nutrients and oxygen to growing tumors. The Hypoxia-Inducible Factor (HIF) pathway is activated in response to low oxygen levels in tumors and induces the expression of genes that promote angiogenesis, including Vascular Endothelial Growth Factor (VEGF) [6].

Transcription factors often rely on co-activators and co-repressors to exert their effects on gene expression. These co-regulators can be targeted to modulate transcription factor activity. For example, BRD4, a co-activator of MYC, has been identified as a promising target in cancers with MYC dysregulation [7]. Inhibitors of BET (Bromodomain and Extraterminal) proteins, which interact with BRD4, are showing promise in preclinical models and early-phase clinical trials for MYC-driven cancers. CRISPR-Cas9 and other gene-editing technologies provide a powerful tool for targeting transcription factors at the genetic level. CRISPR-based approaches can be used to knock out or correct mutations in transcription factors that drive tumorigenesis [8].

Transcription factors can be modulated by epigenetic changes such as DNA methylation and histone modification. Small molecules that target epigenetic regulators, like Histone Deacetylase (HDAC) inhibitors or DNA methyltransferase inhibitors, are being investigated as potential cancer therapies [9]. These agents can alter the chromatin landscape, enhancing or inhibiting transcription factor binding to their target genes. By manipulating the epigenetic regulation of transcription factors, it may be possible to restore the expression of tumorsuppressive genes or inhibit oncogenic pathways [10].

Conclusion

Transcription factors are central to the regulation of gene expression and play a critical role in tumorigenesis by controlling processes such as cell proliferation, survival, metastasis, and angiogenesis. Given their essential involvement in cancer biology, transcription factors represent attractive targets for therapeutic intervention. Although significant challenges remain in targeting transcription factors directly, the development of small molecule inhibitors, gene editing technologies, and immunotherapy strategies for improving cancer treatment and patient outcomes

References

1. Vishnoi K, Viswakarma N, Rana A, Rana B. Transcription factors in cancer development and therapy. Cancers. 2020;12(8):2296.

   [Crossref] [Google Scholar] [PubMed]

2. Redell MS, Tweardy DJ. Targeting transcription factors for cancer therapy. Curr Pharm Des. 2005;11(22):2873-2887.

   [Crossref] [Google Scholar] [PubMed]

3. Sabol M, Trnski D, Musani V, Ozretic P, Levanat S. Role of GLI transcription factors in pathogenesis and their potential as new therapeutic targets. Int J Mol Sci. 2018;19(9):2562.

   [Crossref] [Google Scholar] [PubMed]

4. Zhang Z, Li M, Rayburn ER, Hill DL, Zhang R, Wang H. Oncogenes as novel targets for cancer therapy (Part III) Transcription factors. Am J Pharmacogenomics. 2005;5:327-338.

   [Crossref] [Google Scholar] [PubMed]

5. Leaner VD, Donninger H, Birrer MJ. Transcription factors as targets for cancer therapy: AP-1 a potential therapeutic target. Curr Cancer Ther Rev. 2007;3(1):1-6.

   [Crossref] [Google Scholar]

6. Libermann TA, Zerbini LF. Targeting transcription factors for cancer gene therapy. Curr Gene Ther. 2006;6(1):17-33.

   [Crossref] [Google Scholar] [PubMed]

7. Xu H, Liu L, Li W, Zou D, Yu J, Wang L, et al. Transcription factors in colorectal cancer: molecular mechanism and therapeutic implications. Oncogene. 2021;40(9):1555-1569.

   [Crossref] [Google Scholar] [PubMed]

8. Deng L, Meng T, Chen L, Wei W, Wang P. The role of ubiquitination in tumorigenesis and targeted drug discovery.  Signal Transduct Target Ther. 2020;5(1):11.

   [Crossref] [Google Scholar] [PubMed]

9. Turner DP, Watson DK. ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer. Expert Rev Anticancer Ther. 2008;8(1):33-42.

   [Crossref] [Google Scholar] [PubMed]

10. Garg AA, Aggarwal BB. Nuclear transcription factor-κB as a target for cancer drug development. Leukemia. 2002;16(6):1053-1068.

    [Crossref] [Google Scholar] [PubMed]